NEUROTECH INTERNATIONAL LIMITED (ASX: NTI)
Health care · News and insights
Price unavailable
Latest NTI announcements
Announcement Insights
Neurotech Starts Phase 3 Autism Trial With Funding Intended to Reach Data Readout
Neurotech has begun dosing patients in its pivotal Phase 3 autism trial, with funding expected to support development through the top-line readout. The October 28 update also reported US FDA clearance to begin a proposed clinical program, patent allowances and financing commitments; shareholders later approved placement-related resolutions at the AGM.}
Updated 11 Nov 2026, 01:45 PM Sydney time
Sources
Change of Director's Interest NoticeFinal Director's Interest NoticeResults of MeetingQuarterly Activities/Appendix 4C Cash Flow ReportComments
2026-11-11 · Health care
NTI: $0.019 +18.75% · MC: $31M
Neurotech International director Andrew Chapman acquired one million shares on-market, increasing the holding in a related entity from two million to three million shares. The company’s shares rose around 19% on the day, alongside the update.
Updated 2026-11-11 13:43
Sources
Change of Director's Interest NoticeComments
2026-11-06 · Health care
NTI: $0.016 -5.88% · MC: $31M
Robert Maxwell Johnston ceased to be a director of Neurotech International Limited on 5 November; his final interest notice records 4.6 million ordinary shares held by a related entity. The company’s recent quarterly update said it expected to be funded through the top-line readout of its Phase 3 autism trial, which has begun dosing.
Updated 2026-11-06 15:09
Sources
Final Director's Interest NoticeComments
2026-11-05 · Health care
NTI: $0.017 +6.25% · MC: $31M
Neurotech International shareholders passed all resolutions put to a poll at the annual meeting, including director elections, placement-related approvals and options issues. The company’s latest quarterly update said its pivotal Phase 3 autism trial had begun dosing and it had secured funding intended to support development through the trial’s top-line results.
Updated 2026-11-05 11:41
Sources
Results of MeetingComments
2026-10-28 · Health care
NTI: $0.018 -5.26% · MC: $31M
Neurotech International has dosed the first patient in its Phase 3 autism trial of NTI164, with all Australian sites initiated and up to 200 participants planned. The company also received US FDA clearance to begin a proposed clinical program and patent allowances, while securing a loan and placement commitments to support development; it says current funding is expected to last through the trial’s top-line data readout.
Updated 2026-10-28 08:26
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
Comments